The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality

OBJECTIVE: To compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5 alpha-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings. METHODS: We employed a retrospective matched cohort study in 4 regions of an integra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Urology
Main Authors: Wallner, Lauren P., DiBello, Julia R., Li, Bonnie H., Van Den Eeden, Stephen K., Weinmann, Sheila, Ritzwoller, Debra P., Abell, Jill E., D’Agostino, Ralph, Loo, Ronald K., Aaronson, David S., Horwitz, Ralph I., Jacobsen, Steven J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080272/
https://ncbi.nlm.nih.gov/pubmed/29906480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2018.05.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados